ATE329587T1 - Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen - Google Patents

Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen

Info

Publication number
ATE329587T1
ATE329587T1 AT01953150T AT01953150T ATE329587T1 AT E329587 T1 ATE329587 T1 AT E329587T1 AT 01953150 T AT01953150 T AT 01953150T AT 01953150 T AT01953150 T AT 01953150T AT E329587 T1 ATE329587 T1 AT E329587T1
Authority
AT
Austria
Prior art keywords
compositions
osteoporosis
treatment
inflammatory joint
component
Prior art date
Application number
AT01953150T
Other languages
English (en)
Inventor
Herwig Buchholz
Jerzy Meduski
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE329587T1 publication Critical patent/ATE329587T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01953150T 2000-06-02 2001-05-19 Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen ATE329587T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20857200P 2000-06-02 2000-06-02

Publications (1)

Publication Number Publication Date
ATE329587T1 true ATE329587T1 (de) 2006-07-15

Family

ID=22775091

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01953150T ATE329587T1 (de) 2000-06-02 2001-05-19 Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen

Country Status (11)

Country Link
US (1) US6812215B2 (de)
EP (1) EP1286667B1 (de)
JP (1) JP2003534373A (de)
KR (1) KR100814652B1 (de)
AT (1) ATE329587T1 (de)
AU (1) AU7566601A (de)
BR (1) BR0111210A (de)
CA (1) CA2410885C (de)
DE (1) DE60120691T2 (de)
ES (1) ES2266220T3 (de)
WO (1) WO2001091734A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004538262A (ja) * 2000-12-14 2004-12-24 タフツ ユニバーシティー 関節炎状態を治療するための化合物および方法
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
KR100946822B1 (ko) * 2002-05-01 2010-03-09 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 칼슘 함유 조직 강화제 및 그 용도
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
KR20050081595A (ko) * 2004-02-16 2005-08-19 한국 메디텍 제약 주식회사 캄페롤을 유효성분으로 함유하는 골다공증치료제
EP1750527A1 (de) * 2004-03-11 2007-02-14 Wiley Organics, Inc. Zusammensetzung und methode zur verbesserung der bioverfügbarkeit von calcium und magnesium in dietätischen erzeugnissen und lebensmittelzusätzen
RU2268053C1 (ru) * 2004-05-05 2006-01-20 Григорий Николаевич Коныгин Способ лечения гипокальциемий, остеопорозов, переломов
WO2006055672A2 (en) * 2004-11-16 2006-05-26 Limerick Neurosciences, Inc. Methods and compositions for treating pain
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
WO2006079243A1 (fr) * 2005-01-26 2006-08-03 Mian Long Emploi du flavonol et des glycosides de type flavonol dans la stimulation de la croissance des cellules épithéliales rénales tubulaires pour sécréter le facteur de croissance osseuse
WO2006099233A2 (en) * 2005-03-10 2006-09-21 Sciele Pharma, Inc. Compositions and methods for the treatment of osteoporosis and inflammatory joint disease
US20060216361A1 (en) * 2005-03-10 2006-09-28 Edwards John B Compositions and methods for the treatment of osteoporosis and inflammatory joint disease
WO2008057738A1 (en) * 2006-10-27 2008-05-15 Sciele Pharma, Inc. Isoflavone-containing compositions for the treatment of osteoporosis and inflammatory joint disease
DE102007029042A1 (de) * 2007-06-21 2008-12-24 Analyticon Discovery Gmbh Pharmazeutische Zusammensetzung mit einem Trihydroxychromenone-Derivate
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US8496964B2 (en) * 2009-02-27 2013-07-30 Council Of Scientific & Industrial Research Controlled release micro-capsule for osteogenic action
EP2696865B1 (de) 2011-04-13 2016-12-21 Thermolife International, LLC Verwendungsverfahren für n-acetyl-beta-alanin
EP2799060A1 (de) 2013-04-30 2014-11-05 Aprofol AG Stabile hochdosierte pharmazeutische Zusammensetzung enthaltend Levoleucovorin
EP2799061A1 (de) 2013-04-30 2014-11-05 Aprofol AG Stabile pharmazeutische Hochdosiszusammensetzungen enthaltend Folate
WO2016182262A2 (ko) * 2015-05-14 2016-11-17 주식회사 아모레퍼시픽 관절 기능 향상용 조성물
US20190015448A1 (en) * 2017-07-13 2019-01-17 Summit Innovation Labs LLC Treatment and Prevention of Bone and Joint Disorders
US11007171B2 (en) * 2017-07-13 2021-05-18 Summit Innovation Labs, LLC Treatment and prevention of joint disorders
CN120241688A (zh) 2018-01-12 2025-07-04 麦提麦迪制药有限公司 乳酸钙在制备用于治疗疾病的药物组合物、食物或营养组合物中的用途
WO2020112828A1 (en) 2018-11-30 2020-06-04 Zwicker Jeffrey I Compositions and methods for reducing major thrombotic events in cancer patients
CN111084780A (zh) * 2020-01-09 2020-05-01 昆明医科大学 老鹳草素在制备治疗骨质疏松合并骨折的药物中的用途
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
US12156886B2 (en) 2020-11-12 2024-12-03 Thermolife International, Llc Methods of increasing blood oxygen saturation
EP4247390A1 (de) * 2020-11-18 2023-09-27 Société des Produits Nestlé S.A. Zusammensetzungen und verfahren mit einer kombination aus oleuropein und quercetin zur verwendung bei knorpeldegeneration
IL315206A (en) 2021-02-11 2024-10-01 Thermolife Int Llc A method of administering nitric oxide gas
JP2022186528A (ja) * 2021-06-04 2022-12-15 セトラスホールディングス株式会社 微粒子水酸化マグネシウムを含む殺菌性組成物及び破骨細胞分化抑制用組成物
GR1011003B (el) * 2024-02-28 2025-07-22 Cloudpharm Private Company, Συμπληρωμα διατροφης για την αντιμετωπιση της απωλειας της οστικης πυκνοτητας (οστεοπενια)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US25764A (en) * 1859-10-11 Improvement in cultivators
US5478579A (en) * 1991-02-06 1995-12-26 Biodyn Medical Research, Inc. Method for treatment of osteoporosis
US5807586A (en) * 1996-07-30 1998-09-15 Energetics, Inc. Method of dietary supplementation
JPH10117727A (ja) * 1996-10-16 1998-05-12 Snow Brand Milk Prod Co Ltd ミネラル組成物及びその製造法
JP2000041679A (ja) * 1998-07-31 2000-02-15 Nissho Corp 骨密度の予測方法
CA2348693C (en) * 1998-10-19 2008-07-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid
JP5220968B2 (ja) * 1998-10-30 2013-06-26 ヨーロピアン ブランド パティスィペイションズ エス ア 心臓血管疾患の治療および予防のための組成物
JP2002187846A (ja) * 2000-10-12 2002-07-05 Nippon Kayaku Co Ltd 組成物及びそれを含有する食品、抗関節炎剤、抗リュウマチ剤又は飼料

Also Published As

Publication number Publication date
ES2266220T3 (es) 2007-03-01
WO2001091734A8 (en) 2003-12-18
US20030139354A1 (en) 2003-07-24
KR100814652B1 (ko) 2008-03-18
AU7566601A (en) 2001-12-11
DE60120691T2 (de) 2007-06-06
WO2001091734A2 (en) 2001-12-06
KR20040012430A (ko) 2004-02-11
EP1286667B1 (de) 2006-06-14
CA2410885A1 (en) 2001-12-06
BR0111210A (pt) 2003-12-16
DE60120691D1 (de) 2006-07-27
EP1286667A2 (de) 2003-03-05
US6812215B2 (en) 2004-11-02
CA2410885C (en) 2010-07-13
WO2001091734A3 (en) 2002-12-05
JP2003534373A (ja) 2003-11-18

Similar Documents

Publication Publication Date Title
DE60120691D1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DK1233770T3 (da) Phosphonatforbindelser
MX9803851A (es) Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
CL2004000437A1 (es) Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast
WO2003009855A3 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
MXPA05004247A (es) Cromonas y derivados de cromona y usos de los mismos.
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
DE60307749D1 (de) Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem
BR9815596A (pt) Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
MXPA05010515A (es) Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
ES2189165T3 (es) Nuevos compuestos macrociclicos como inhibidores de metaloproteasa.
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
NO20010940D0 (no) TAN-1057 derivater
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE406158T1 (de) Verwendung von vitamin c zur behandlung der charcot-marie-tooth krankheit
TR200200278T2 (tr) Kalsilitik bileşimler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties